Table 1.
Largest series comparing the ability of whole-body FDG PET with conventional imaging to detect locoregional and distant recurrences in patients who have previously undergone primary treatment for breast cancer.
| Series | Number of patients | Confirmed positive/negative cases | FDG PET Sensitivity (TP/TP+FN)* |
FDG PET Specificity (TN/TN+FP)* |
|---|---|---|---|---|
| Bender 19972 | 75 | 60/15 | 95% (41/43) | 96% (213/221) |
| Moon 19983 | 57 | 29/28 | 93% (27/29) | 79% (22/28) |
| Lonneux 20004† | 39 | 33/6 | 94% (31/33) | 50% (3/6) |
| Kim 20015 | 27 | 17/10 | 94% (16/17) | 80% (8/10) |
| Lin 20026 | 36 | 11/25 | 85% (23/27) | 96% (85/89) |
| Liu 20027† | 30 | 28/2 | 96% (25/28) | 50% (1/2) |
| Suarez 20028† | 38 | 26/12 | 92% (24/26) | 75% (9/12) |
| Vranjesevic13 2002 | 61 | 42/19 | 93% (39/42) | 84% (16/19) |
| Gallowitsch 20039 | 62 | 34/28 | 97% (33/34) | 82% (23/28) |
| Siggelkow 200310 | 57 | 31/26 | 81% (25/31) | 98% (25/26) |
| Kamel 200311 | 60 | 43/17 | 89% (24/27) LRR** 100% (26/26) DM†† |
84% (16/19) LRR 97% (30/31) DM |
| Wolfort 200615 | 23 | 16/7 | 81% (13/16) | 100% (7/7) |
| Mahner 200814*** | 119 | 71/48 | 87% (62/71) | 83% (40/48) |
*
Values calculated on patient analysis except for Bender and Lin series which are calculated on lesion analysis; TP=true positive, TN=true negative, FP=false positive, FN=false negative
†
Patients were mostly or all asymptomatic with elevated tumor markers.
**
LRR=Locoregional recurrence
††
DM=Distant metastases
***
50/119 patients had undergone primary treatment